{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:21:00Z","timestamp":1791091260749,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1111,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly"},{"name":"Guerbet Medical"},{"name":"Medtronic"},{"name":"Boston Scientific"},{"name":"Cordis"},{"name":"Stago"},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly"},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly"},{"name":"Guerbet Medical"},{"name":"Medtronic"},{"name":"Boston Scientific"},{"name":"Cordis"},{"name":"Stago"},{"name":"Centocor"},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ITC Edison"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.jacc.2009.12.071","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T05:31:35Z","timestamp":1277875895000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":315,"title":["Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration"],"prefix":"10.1016","volume":"56","author":[{"given":"Jean-S\u00e9bastien","family":"Hulot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bellemain-Appaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cayla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Beygui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2009.12.071_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.12.071_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.12.071_bib3","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.12.071_bib4","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","article-title":"Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects","volume":"5","author":"Fontana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.12.071_bib7","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2009.12.071_bib8","first-page":"589","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"64","author":"Kim","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.12.071_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.12.071_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2009.12.071_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2009.12.071_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2009.12.071_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.12.071_bib16","first-page":"A27","article-title":"Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel (abstr)","volume":"53 Suppl A","author":"Anderson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2009.12.071_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2009.12.071_bib20","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2009.12.071_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2009.12.071_bib22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study","volume":"54","author":"Cuisset","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2009.12.071_bib24","first-page":"406","article-title":"Minimal clinically important differences: review of methods","volume":"28","author":"Wells","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacc.2009.12.071_bib25","series-title":"The Cochrane Handbook for Systematic Reviews of Interventions. Version 4.2.0","author":"Clarke","year":"2003"},{"key":"10.1016\/j.jacc.2009.12.071_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0169-2607(97)00016-3","article-title":"EasyMA: a program for the meta-analysis of clinical trials","volume":"53","author":"Cucherat","year":"1997","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jacc.2009.12.071_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2009.12.071_bib28","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2009.12.071_bib29","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.12.071_bib30","first-page":"327","article-title":"The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the VerifyNow P2Y12 near-patient testing device in patients undergoing coronary angiography (abstr)","volume":"30","author":"Worrall","year":"2009","journal-title":"Eur H J"},{"key":"10.1016\/j.jacc.2009.12.071_bib31","unstructured":"Bhatt DL. Charisma Genomic Substudy. Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2009; San Francisco, CA."},{"key":"10.1016\/j.jacc.2009.12.071_bib32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"30","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2009.12.071_bib33","first-page":"A335","article-title":"Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting (abstr)","volume":"53","author":"Tsiaousis","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2009.12.071_bib34","first-page":"A27","article-title":"Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry (abstr)","volume":"53","author":"Ramirez","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2009.12.071_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jacc.2009.12.071_bib36","first-page":"S815","article-title":"Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial (abstr)","volume":"118","author":"Dunn","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib37","doi-asserted-by":"crossref","first-page":"S815","DOI":"10.1161\/circ.118.suppl_18.S_815","article-title":"Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study (abstr)","volume":"118","author":"Aubert","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.12.071_bib39","first-page":"92","article-title":"Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel (abstr)","volume":"30","author":"Banerjee","year":"2009","journal-title":"Eur H J"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.12.071_bib40","first-page":"444","article-title":"Proton pump inhibitors in patients treated with aspirin and clopidogrel (abstr)","volume":"30","author":"Gaspar","year":"2009","journal-title":"Eur H J"},{"issue":"Suppl","key":"10.1016\/j.jacc.2009.12.071_bib41","first-page":"150","article-title":"Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors (abstr)","volume":"30","author":"Sarafoff","year":"2009","journal-title":"Eur H J"},{"key":"10.1016\/j.jacc.2009.12.071_bib42","unstructured":"Bhatt DL. Clopidogrel and the Optimization of GI Events Trial (COGENT). Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2009; San Francisco, CA."},{"key":"10.1016\/j.jacc.2009.12.071_bib43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","article-title":"Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications","volume":"115","author":"L\u00fcscher","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib44","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/CIRCULATIONAHA.105.600155","article-title":"Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents","volume":"113","author":"Kuchulakanti","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib45","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"Grines","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2009.12.071_bib46","first-page":"484","article-title":"Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19","volume":"70","author":"Furata","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2009.12.071_bib47","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710016050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710016050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:38:53Z","timestamp":1760013533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710016050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0735109710016050"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2009.12.071","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2009.12.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}